DECR and JNCC conduct assessment of Queen Conch populations in TCI

BEGINS

 

PRESS RELEASE

 

DECR and JNCC conduct assessment of Queen Conch populations in TCI 

 

The Turks and Caicos Islands (TCI) have commercially fished for Caribbean spiny lobster, Queen conch and various fin fish species as source of protein and income.  The Lobatus gigas, Queen conch continues to be one of the two major economically important fisheries for the Turks and Caicos Islands.  However, throughout the Caribbean region, the Queen conch has been declining in abundance.  The TCI is not immune to the limitations of the species and has therefore been taking steps to evaluate the population of the Queen conch in the TCI. 

 

The Department of Environment and Coastal Resources (DECR) has been conducting a piloted visual assessment of the Queen conch on the Caicos Bank to assist in determining the current status of the species in the TCI.  Additionally, the Department in collaboration with the Joint Nature Conservation Committee (JNCC), has submitted a proposal for additional funding to continue an assessment to obtain more abundance information, local consumption patterns, biological data and trade restrictions specific to the Queen conch.

 

END

 

DEPARTMENT OF TRADE, INDUSTRY AND CONSUMER AFFAIRS HOSTS TRAINING IN STRATEGIC TRADE AND INVESTMENT

BEGINS

 

PRESS RELEASE

 

DEPARTMENT OF TRADE, INDUSTRY AND CONSUMER AFFAIRS HOSTS TRAINING IN STRATEGIC TRADE AND INVESTMENT

 

The Department of Trade, Industry and Consumer Affairs hosted training on the Professional Certificate in Strategic Trade and Investment from 28 September to 2 October, 2020. The training was delivered virtually by the UK-based International Centre for Parliamentary Studies (ICPS) to middle and senior management professionals from across the Turks and Caicos Islands Government.

 

There were 13 participants from the Department of Trade, Industry and Consumer Affairs, InvestTCI, Customs Department, Attorney General’s Chambers and the Strategic Policy and Planning Department. The training supported participants’ understanding of key themes including multilateral trade agreements and the fundamental principles of trade and investment strategies.

 

Having completed the week-long training, the participants are also eligible for professional membership to the Institute of Leadership and Management allowing them access to a suite of leadership, management and coaching resources.

 

Commenting on the training, the Director of Trade and Head of the Department of Trade, Industry and Consumer Affairs, Mrs Merida Cable-Lewis stated; “International trade and foreign direct investment (FDI) are drivers of the global economy. The recently held Professional Certificate in Strategic Trade and Investment course was therefore aimed at providing advanced training in the areas of international trade and FDI to encourage enhanced stakeholder engagement on the development and delivery of trade and investment strategies designed to achieve sustainable economic growth in the Turks and Caicos Islands.

 

“An objective that is particularly significant in light of the Covid-19 pandemic and the United Kingdom’s exit from the European Union (Brexit) which have both presented unprecedented challenges to the global economy and world trade.

 

“Following its establishment in May 2019, the Department has made significant strides in its efforts to develop and promote trade in the Turks and Caicos Islands. This has been achieved through capacity building initiatives for the MSME sector, encouraging the growth of alternative industries, working to develop policy, legal and institutional frameworks to support trade activity and assisting with the negotiation of bilateral and multilateral trade agreements.

 

“We are grateful to the Ministry of Finance, Trade and Investment for its support of this initiative.”

 

ENDS

DRUG RECALL: DIABETIC DRUG - METFORMIN EXTENDED RELEASE

BEGINS

 

NEWS RELEASE

 

DRUG RECALL: DIABETIC DRUG - METFORMIN EXTENDED RELEASE

 

As a follow up to our previous Press Release (issued on Friday, 17th July 2020) captioned drug recall: diabetic drug metformin extended-release, the Ministry of Health, Agriculture, Sports and Human Services (MoHASHS) wishes to inform the public that recent checks have revealed that none of these reported products are currently in circulation in the TCI market. The list of recalled products is attached. Metformin is a prescription type drug used to control high blood sugar in patients with type 2 diabetes.

 

These recalls are due to the possibility of the impurity, known as N-nitroso dimethylamine (NDMA), being found in these metformin formulations. NDMA is classified as a probable cancer-causing agent (carcinogen) based on results from laboratory tests.

 

In spite our findings, the MoHASHS wishes to caution healthcare providers and the public to remain alert regarding this recall. If these metformin products enter the local market, providers are asked to remove them from their shelves and stop all supply, distribution and sale to the public. Patients who are currently taking this medicine are reminded to always seek the advice of their physicians, pharmacists or other healthcare providers if they have any concerns. The MoHASHS wishes to advise that there are other suitable alternative treatment options available in the Turks and Caicos Islands.

 

The MoHASHS’ top priority is to ensure patient safety and we will continue to monitor this situation as investigations continue.

 

For more information regarding the regulation of drugs/medicines, please contact the National Pharmacist, Andre Morgan at 338-3072.

 

 

Company

Medicine

NDC

Lot Number

Expiration

Amneal Pharmaceuticals

Metformin HCl 500 mg  Extended Release Tablets, 100 count bottle

53746-178-01

All Lots

06/2020-07/2021

Amneal Pharmaceuticals

Metformin HCl 500 mg  Extended Release Tablets, 500 count bottle

53746-178-05

All Lots

Jun-20

Amneal Pharmaceuticals

Metformin HCl 500 mg  Extended Release Tablets, 1000 count bottle

53746-178-10

All Lots

06/2020-09/2020

Amneal Pharmaceuticals

Metformin HCl 500 mg  Extended Release Tablets, 90 count bottle

53746-178-90

All Lots

06/2020-04/2021

Amneal Pharmaceuticals

Metformin HCl 500 mg  Extended Release Tablets, Bulk box

53746-178-Bulk

All Lots

06/2020-02/2021

Amneal Pharmaceuticals

Metformin HCl 500 mg  Extended Release Tablets, 90 count bottle

65162-178-09

All Lots

01/2021-09/2021

Amneal Pharmaceuticals

Metformin HCl 500 mg  Extended Release Tablets, 100 count bottle

65162-178-10

All Lots

09/2020-02/2022

Amneal Pharmaceuticals

Metformin HCl 500 mg  Extended Release Tablets, 1000 count bottle

65162-178-11

All Lots

11/2020-10/2021

Amneal Pharmaceuticals

Metformin HCl 500 mg  Extended Release Tablets, 500 count bottle

65162-178-50

All Lots

06/2020-02/2022

Amneal Pharmaceuticals

Metformin HCl 750 mg  Extended Release Tablets, 100 count bottle

53746-179-01

All Lots

06/2020-12/2020

Amneal Pharmaceuticals

Metformin HCl 750 mg  Extended Release Tablets, Bulk box

53746-179-Bulk

All Lots

07/2020-01/2021

Amneal Pharmaceuticals

Metformin HCl 750 mg  Extended Release Tablets, 100 count bottle

65162-179-10

All Lots

10/2020-12/2021

Apotex Corp

Metformin HCl 500 mg Extended Release Tablet, 100 count bottle

60505-0260-1

All Lots

06/2020-04/2021

AVKARE Inc (Amneal)

Metformin HCl 500 mg Extended-Release Tablet, 360 count bottle

42291-610-36 

All Lots

06/2020-02/2022

AVKARE Inc (Amneal)

Metformin HCl 500 mg Extended-Release Tablet, 180 count bottle

42291-610-18

All Lots

06/2020-02/2022

AVKARE Inc (Amneal)

Metformin HCl 500 mg Extended-Release Tablet, 90 count bottle

42291-610-90

All Lots

06/2020-02/2022

AVKARE Inc (Amneal)

Metformin HCl 500 mg Extended-Release Tablet, 1000 count bottle

42291-610-10

All Lots

07/2020-02/2022

AVKARE Inc (Amneal)

Metformin HCl 500 mg Extended-Release Tablet, 50 count unit dose

50268-531-15

All Lots

06/2020-07/2021

AVKARE Inc (Amneal)

Metformin HCl 750 mg Extended-Release Tablet, 90 count bottle

42291-611-90 

All Lots

11/2020-01/2022

AVKARE Inc (Amneal)

Metformin HCl 750 mg Extended-Release Tablet, 500 count bottle

42291-611-50 

All Lots

06/2020-01/2022

AVKARE Inc (Amneal)

Metformin HCl 750 mg Extended-Release Tablet, 180 count bottle

42291-611-18 

All Lots

06/2020-01/2022

Granules Pharmaceuticals

Metformin HCl 750 mg Extended-Release Tablet, 100 count bottle

70010-492-01

All lots

05/2021-01/2023

Granules Pharmaceuticals

Metformin HCl 750 mg Extended-Release Tablet, 500 count bottle

70010-492-05

4920005B

Jun-21

Lupin Pharmaccetuclas

Metformin HCL 1000 mg Extended-Release Tablets, 60 count bottle

68180-337-07 

All lots

07/2020-01/2022

Lupin Pharmaceutical

Metformin HCl 500 mg Extended-Release Tablet, 60 count bottle

68180-336-07

G901203

Dec-20

Lupin Pharmaceuticals

Metformin HCL 500 mg Extended-Release Tablets, 100 count bottle

68180-338-01

All lots

08/2022-02/2022

Lupin Pharmaceuticals

Metformin HCL 500 mg Extended-Release Tablets, 60 count bottle

68180-336-07 

All lots

08/2020-02/2022

Lupin Pharmaceuticals

Metformin HCL 1000 mg Extended-Release Tablets, 90 count bottle

68180-339-09

All lots

07-2020-02/2022

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 100 count bottle

49483-623-01

XP9004

Dec-20

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 500 count bottle

49483-623-50

E037F

Oct-20

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 90 count bottle

49483-623-09

E072F

Oct-20

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 90 count bottle

49483-623-09

E074F

Oct-20

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 1000 count bottle

49483-623-10

D086F

Oct-20

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 500 count bottle

49483-623-50

G011F

Oct-20

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 90 count bottle

49483-623-09

E076F

Oct-20

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 100 count bottle

49483-623-01

XP8260

Oct-20

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 1000 count bottle

49483-623-10

G012F

Nov-20

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 90 count bottle

49483-623-09

D096F

Nov-20

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 90 count bottle

49483-623-09

XP8276

Nov-20

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 500 count bottle

49483-623-50

F001F

Nov-20

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 90 count bottle

49483-623-09

H029F

Nov-20

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 90 count bottle

49483-623-09

H031F

Nov-20

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 90 count bottle

49483-623-09

XP8289

Nov-20

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 500 count bottle

49483-623-50

H041F

Dec-20

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 90 count bottle

49483-623-09

L007F

Dec-20

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 1000 count bottle

49483-623-10

L008F

Dec-20

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 500 count bottle

49483-623-50

L009F

Dec-20

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 90 count bottle

49483-623-09

J022F

Dec-20

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 90 count bottle

49483-623-09

H039F

Dec-20

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 90 count bottle

49483-623-09

J092F

Jan-21

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 1000 count bottle

49483-623-10

K042F

Feb-21

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 500 count bottle

49483-623-50

K051F

Jun-21

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 90 count bottle

49483-623-09

L055F

Jun-21

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 90 count bottle

49483-623-09

K079F

Jul-21

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 1000 count bottle

49483-623-10

M001F

Jul-21

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 90 count bottle

49483-623-09

A002G

Aug-21

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 90 count bottle

49483-623-09

A003G

Aug-21

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 90 count bottle

49483-623-09

A007G

Aug-21

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 500 count bottle

49483-623-50

A115G

Sep-21

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 500 count bottle

49483-623-50

A010G

Sep-21

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 1000 count bottle

49483-623-10

A009G

Sep-21

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 90 count bottle

49483-623-09

A49001

Nov-21

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 90 count bottle

49483-623-09

A40001

Dec-21

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 1000 count bottle

49483-623-10

A40002

Dec-21

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 100 count bottle

49483-623-01

XP0010

Dec-21

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 90 count bottle

49483-623-09

A40003

Dec-21

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 1000 count bottle

49483-623-10

A40004

Dec-21

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 100 count bottle

49483-623-01

XP0016

Dec-21

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 90 count bottle

49483-623-09

A40005

Dec-21

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 500 count bottle

49483-623-50

A40006

Jan-22

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 500 count bottle

49483-623-50

A40007

Jan-22

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 500 count bottle

49483-623-50

A40008

Jan-22

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 90 count bottle

49483-623-09

A40009

Feb-22

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 90 count bottle

49483-623-09

A40010

Mar-22

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 90 count bottle

49483-623-09

XP0036

Mar-22

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 500 count bottle

49483-623-50

A40011

Mar-22

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 1000 count bottle

49483-623-10

A40012

Mar-22

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 100 count bottle

49483-623-01

XP0046

Apr-22

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 90 count bottle

49483-623-09

A40013

Mar-22

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 1000 count bottle

49483-623-10

A40014

Apr-22

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 90 count bottle

49483-623-09

A40015

Apr-22

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 500 count bottle

49483-623-50

A40016

Apr-22

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 1000 count bottle

49483-623-10

A40017

Apr-22

Marksans Pharma Limited

Metformin HCl 500 mg Extended-Release Tablets, 500 count bottle

49483-623-50

A40018

Apr-22

Marksans Pharma Limited

Metformin HCl 750 mg Extended-Release Tablets, 100 count bottle

49483-624-01

M125E

Oct-20

Marksans Pharma Limited

Metformin HCl 750 mg Extended-Release Tablets, 100 count bottle

49483-624-01

D001F

Nov-20

Marksans Pharma Limited

Metformin HCl 750 mg Extended-Release Tablets, 100 count bottle

49483-624-01

C084F

Nov-20

Marksans Pharma Limited

Metformin HCl 750 mg Extended-Release Tablets, 100 count bottle

49483-624-01

F073F

Jan-21

Marksans Pharma Limited

Metformin HCl 750 mg Extended-Release Tablets, 100 count bottle

49483-624-01

E063F

Jan-21

Marksans Pharma Limited

Metformin HCl 750 mg Extended-Release Tablets, 100 count bottle

49483-624-01

F072F

Mar-21

Marksans Pharma Limited

Metformin HCl 750 mg Extended-Release Tablets, 100 count bottle

49483-624-01

J002F

Apr-21

Marksans Pharma Limited

Metformin HCl 750 mg Extended-Release Tablets, 100 count bottle

49483-624-01

J087F

Apr-21

Marksans Pharma Limited

Metformin HCl 750 mg Extended-Release Tablets, 100 count bottle

49483-624-01

K080F

Jun-21

Marksans Pharma Limited

Metformin HCl 750 mg Extended-Release Tablets, 100 count bottle

49483-624-01

L056F

Jun-21

Marksans Pharma Limited

Metformin HCl 750 mg Extended-Release Tablets, 100 count bottle

49483-624-01

M046F

Jul-21

Marksans Pharma Limited

Metformin HCl 750 mg Extended-Release Tablets, 100 count bottle

49483-624-01

9R9001

Oct-21

Marksans Pharma Limited

Metformin HCl 750 mg Extended-Release Tablets, 100 count bottle

49483-624-01

9R9002

Nov-21

Marksans Pharma Limited

Metformin HCl 750 mg Extended-Release Tablets, 100 count bottle

49483-624-01

9R0001

Dec-21

Marksans Pharma Limited

Metformin HCl 750 mg Extended-Release Tablets, 100 count bottle

49483-624-01

9R0002

Dec-21

Marksans Pharma Limited

Metformin HCl 750 mg Extended-Release Tablets, 100 count bottle

49483-624-01

9R0003

Mar-22

Marksans Pharma Limited

Metformin HCl 750 mg Extended-Release Tablets, 100 count bottle

49483-624-01

XR0016

Mar-22

Marksans Pharma Limited

Metformin HCl 750 mg Extended-Release Tablets, 100 count bottle

49483-624-01

9R0004

Mar-22

Marksans Pharma Limited

Metformin HCl 750 mg Extended-Release Tablets, 100 count bottle

49483-624-01

9R0005

Mar-22

Marksans Pharma Limited

Metformin HCl 750 mg Extended-Release Tablets, 100 count bottle

49483-624-01

9R0006

Apr-22

Marksans Pharma Limited

Metformin HCl 750 mg Extended-Release Tablets, 100 count bottle

49483-624-01

9R0007

Apr-22

PD-Rx Pharmaceuticals (Amneal)

Metformin HCl 500 mg Extended-Release Tablet, 30 count bottle

43063-0428-30

All Lots

Jun-20

PD-Rx Pharmaceuticals (Amneal)

Metformin HCl 500 mg Extended-Release Tablet, 60 count bottle

43063-0428-60

All Lots

Jun-20

PD-Rx Pharmaceuticals (Amneal)

Metformin HCl 500 mg Extended-Release Tablet, 90 count bottle

43063-0428-90

All Lots

Jun-20

PD-Rx Pharmaceuticals (Amneal)

Metformin HCl 500 mg Extended-Release Tablet, 120 count bottle

43063-0428-98

All Lots

Jun-20

PD-Rx Pharmaceuticals (Amneal)

Metformin HCl 500 mg Extended-Release Tablet, 180 count bottle

43063-0428-93

All Lots

Jun-20

PD-Rx Pharmaceuticals (Amneal)

Metformin HCl 500 mg Extended-Release Tablet, 500 count bottle

53746-0178-05

All Lots

Jun-20

PD-Rx Pharmaceuticals (Marksans)

Metformin HCl 500 mg Extended-Release Tablet, 30 count bottle

72789-009-30

A20B02

Dec-20

PD-Rx Pharmaceuticals (Marksans)

Metformin HCl 500 mg Extended-Release Tablet, 30 count bottle

72789-009-30

I19D03

Dec-20

PD-Rx Pharmaceuticals (Marksans)

Metformin HCl 500 mg Extended-Release Tablet, 30 count bottle

72789-009-30

J19A98

Dec-20

PD-Rx Pharmaceuticals (Marksans)

Metformin HCl 500 mg Extended-Release Tablet, 30 count bottle

72789-009-30

K19E32

Dec-20

PD-Rx Pharmaceuticals (Marksans)

Metformin HCl 500 mg Extended-Release Tablet, 30 count bottle

72789-009-30

L19C86 

Dec-20

PD-Rx Pharmaceuticals (Marksans)

Metformin HCl 500 mg Extended-Release Tablet, 60 count bottle

72789-009-60

I19D55

Dec-20

PD-Rx Pharmaceuticals (Marksans)

Metformin HCl 500 mg Extended-Release Tablet, 60 count bottle

72789-009-60

I19F50

Dec-20

PD-Rx Pharmaceuticals (Marksans)

Metformin HCl 500 mg Extended-Release Tablet, 60 count bottle

72789-009-60

K19A18

Dec-20

PD-Rx Pharmaceuticals (Marksans)

Metformin HCl 500 mg Extended-Release Tablet, 60 count bottle

72789-009-60

K19D87

Dec-20

PD-Rx Pharmaceuticals (Marksans)

Metformin HCl 500 mg Extended-Release Tablet, 60 count bottle

72789-009-60

L19B34

Dec-20

PD-Rx Pharmaceuticals (Marksans)

Metformin HCl 500 mg Extended-Release Tablet, 60 count bottle

72789-009-60

L19D23

Dec-20

PD-Rx Pharmaceuticals (Marksans)

Metformin HCl 500 mg Extended-Release Tablet, 60 count bottle

72789-009-60

L19E74

Dec-20

PD-Rx Pharmaceuticals (Marksans)

Metformin HCl 500 mg Extended-Release Tablet, 90 count bottle

72789-009-90

I19E91

Dec-20

PD-Rx Pharmaceuticals (Marksans)

Metformin HCl 500 mg Extended-Release Tablet, 90 count bottle

72789-009-90

I19F33

Dec-20

PD-Rx Pharmaceuticals (Marksans)

Metformin HCl 500 mg Extended-Release Tablet, 90 count bottle

72789-009-90

J19B88

Dec-20

PD-Rx Pharmaceuticals (Marksans)

Metformin HCl 500 mg Extended-Release Tablet, 90 count bottle

72789-009-90

J19E70

Dec-20

PD-Rx Pharmaceuticals (Marksans)

Metformin HCl 500 mg Extended-Release Tablet, 90 count bottle

72789-009-90

K19D26

Dec-20

PD-Rx Pharmaceuticals (Marksans)

Metformin HCl 500 mg Extended-Release Tablet, 90 count bottle

72789-009-90

L19A65 

Dec-20

PD-Rx Pharmaceuticals (Marksans)

Metformin HCl 500 mg Extended-Release Tablet, 100 count bottle

49483-0623-01

XP9004

Dec-20

PD-Rx Pharmaceuticals (Marksans)

Metformin HCl 500 mg Extended-Release Tablet, 180 count bottle

72789-009-93

I19C21  

Aug-20

PD-Rx Pharmaceuticals (Marksans)

Metformin HCl 500 mg Extended-Release Tablet, 180 count bottle

72789-009-93

I19C57

Dec-20

PD-Rx Pharmaceuticals (Marksans)

Metformin HCl 500 mg Extended-Release Tablet, 180 count bottle

72789-009-93

J19C21

Dec-20

PD-Rx Pharmaceuticals (Marksans)

Metformin HCl 500 mg Extended-Release Tablet, 180 count bottle

72789-009-93

J19C67

Dec-20

PD-Rx Pharmaceuticals (Marksans)

Metformin HCl 500 mg Extended-Release Tablet, 180 count bottle

72789-009-93

K19B53

Dec-20

PD-Rx Pharmaceuticals (Marksans)

Metformin HCl 500 mg Extended-Release Tablet, 180 count bottle

72789-009-93

L19C77

Dec-20

PD-Rx Pharmaceuticals (Marksans)

Metformin HCl 500 mg Extended-Release Tablet, 180 count bottle

72789-009-93

L19E44 

Dec-20

Teva Pharmaceuticals

Metformin HCl 500 mg Extended-Release Tablets, 100 count bottle

62037-571-01

1329548A

Jun-20

Teva Pharmaceuticals

Metformin HCl 500 mg Extended-Release Tablets, 100 count bottle

62037-571-01

1338302M

Oct-20

Teva Pharmaceuticals

Metformin HCl 500 mg Extended-Release Tablets, 100 count bottle

62037-571-01

1348968M

Oct-20

Teva Pharmaceuticals

Metformin HCl 500 mg Extended-Release Tablets, 100 count bottle

62037-571-01

1348969M

Nov-20

Teva Pharmaceuticals

Metformin HCl 500 mg Extended-Release Tablets, 100 count bottle

62037-571-01

1348970M

Oct-20

Teva Pharmaceuticals

Metformin HCl 500 mg Extended-Release Tablets, 100 count bottle

62037-571-01

1376339M

Sep-21

Teva Pharmaceuticals

Metformin HCl 500 mg Extended-Release Tablets, 1000 count bottle

62037-571-10

1323460M

Jun-20

Teva Pharmaceuticals

Metformin HCl 500 mg Extended-Release Tablets, 1000 count bottle

62037-571-10

1330919M

Jun-20

Teva Pharmaceuticals

Metformin HCl 500 mg Extended-Release Tablets, 1000 count bottle

62037-571-10

1338300A

Oct-20

Teva Pharmaceuticals

Metformin HCl 500 mg Extended-Release Tablets, 1000 count bottle

62037-571-10

1341135M

Dec-20

Teva Pharmaceuticals

Metformin HCl 500 mg Extended-Release Tablets, 1000 count bottle

62037-571-10

1391828M

Nov-21

Teva Pharmaceuticals

Metformin HCl 750 mg Extended-Release Tablets, 100 count bottle

62037-577-01

1333338M

Aug-20

Teva Pharmaceuticals

Metformin HCl 750 mg Extended-Release Tablets, 100 count bottle

62037-577-01

1333339A

Aug-20

Teva Pharmaceuticals

Metformin HCl 750 mg Extended-Release Tablets, 1000 count bottle

62037-577-10

1354471A

Feb-21

ENDS

Darwin Plus funding secured for new international partnership project in the Turks and Caicos Islands

BEGINS

 

NEWS RELEASE

 

Darwin Plus funding secured for new international partnership project in the Turks and Caicos Islands

 

An international partnership led by JNCC has recently been awarded Darwin Plus funding to undertake a 3-year project in the Turks and Caicos Islands (TCI). JNCC, the TCI Government Department of Environment and Coastal Resources (DECR), and the South Atlantic Environmental Research Institute (SAERI) will be working together to improve the evidence base in the marine and coastal environments in order to support sustainable coastal and marine management approaches in the islands.

 

Technical assistance will be a key theme of the project; the JNCC’s scientific experts will be working with DECR technical leads to progress expertise in the use of information management, and to develop understanding around natural capital, environmental indicators and status assessments, as well as management approaches in coastal and marine environments. Stakeholder engagement and communicating the outputs of the project will also be central to the project; partners will work with local communities, science professionals and decision-makers to provide in-depth support and build capacity. In addition, new mapping tools are to be developed, and through maximizing the use of, and value of, existing data, these tools will support decision making and the implementation of a new TCI Government Environment Strategy.

 

The JNCC have been working with the UK Overseas Territories for over 20 years, providing technical assistance to support their biodiversity and wider environment management strategies. Specifically, in the TCI, they have developed a focused programme of work over the past few years and have been working with the TCI Government on a range of projects, including disaster resilience and natural capital accounting.

 

This project will form part of a programme of coastal/marine Darwin Plus projects in the islands and will complement marine spatial planning work already underway which is being led by SAERI. There will also be strong links with other natural capital work underway across the Caribbean region.

The project started on 1 August 2020. Further information and updates will be available in due course. 

 

ENDS

PRESS RELEASE: JUDICIAL REVIEW DISMISSED

 

MINISTRY OF INFRASTRUCTURE  HOUSING PLANNING AND DEVELOPMENT

 

DEPARTMENT OF PLANNING

 

 
   

 

 

PRESS RELEASE

 

 

 

On the 1st of October 2020, the Honourable Chief Justice Agyemang made her final ruling in a Judicial Review matter initially heard remotely over two days in July this year.  The applicants, Mr. Eric Le Vin, Mr. Daniel Le Vin and the Proprietors of Strata Plan No. 84 sought judicial review of the decision of the Physical Planning Board to grant Outline Development Permission (‘ODP’), subject to 64 conditions, to “The Yard Limited” to build an Eighty-seven (87) bedroom hotel on parcel 60801/76 in Providenciales.

 

The Respondents the Director of Planning, the Physical Planning Board, the Cabinet of the Turks and Caicos and HE, the Governor of the Turks and Caicos Islands, all of whom were represented by the Attorney General’s Chambers.

“The Yard Limited” who had brought the application for the subject ODP of the hotel were an interested party in the proceedings, they submitted evidence before the Court and also made oral arguments.

 

One of the central points of contention in this case was that this particular application for ODP was for the construction of an Eighty-seven (87) bedroom hotel in an area zoned as (R4) medium density residential (3-6 units per acre), therefore was inconsistent with the land use zoning for the area.

The applicant’s case was that the proposed development would have a negative impact on their properties. They feared that the proposed development would compromise their quality of life in a place where they alleged, they had a legitimate expectation it would remain residential. In addition, they challenged the legality of the grant of ODP, asserting that an application for ODP should not include an application for change of zoning. They further argued that no Environmental Impact Assessment (“EIA”) was conducted prior to the grant of ODP, that it was wrong to grant ODP without a full public consultation. They complained that their lengthy objections were not given due consideration. One of the applicants further claimed that a change of zoning would set a bad precedent and would open a floodgate of others seeking a change of zoning.

 

On behalf of the Respondent’s, Director Dainer Lightbourne deposed an affidavit, his evidence was that the Physical Planning Board (“PPB”) gave full and proper consideration to all matters pertaining to the application. As already mentioned, the application for ODP was for the construction of an eighty seven 87 bedroom room hotel in an area zoned as (R4) medium density residential (3-6 units per acre), therefore was inconsistent with the land use zoning for the area. As a result, if the PPB were minded to grant conditional approval, the application would have to be referred to the Minister for Infrastructure Housing, Planning and Development, pursuant to Section 39(2) of the Physical Planning Ordinance.

 

Section 39(2) procedure requires a referral by an otherwise approving PPB, to the Minister, and through him, to the Governor in Cabinet, for his decision which would come in the form of advice from the Board.

The Director of planning further explained to the Honourable Court that the decision not to require an EIA before the grant of the ODP, was in accordance with an age-old practice, the reason for which is that an EIA involves substantial expense, and the issuance of terms of reference which require the input of stakeholders. One of the 64 conditions of the ODP in this case was not only the requirement of an EIA but also a Comprehensive Impact Assessment (“CIA”), by independent experienced experts in the field.

 

After hearing oral arguments for 2 days on the 28th and 29th of July remotely, the Honourable Chief Justice gave her ruling on the 14th of September where she ruled, among other things, that:

 

  1. That the applicants’ proposition that the Physical Planning Ordinance makes no room for rezoning, so that Cabinet acted unlawfully was misconceived as it was based on two false premises, the first was that the application that found its way to Cabinet, was an application for rezoning of land, and secondly, that the Governor has no power under the PPO to grant a rezoning of land.

 

She found that the application from “The Yard Limited” had never been one for rezoning or change of zoning but rather an application for ODP. The application was inconsistent with the use of land, i.e. residential, was not reason to refuse it, as the existence of Section 39 of the PPO recognizes that such applications may be presented to the PPB.

 

  1. Consideration was given to complaints and concerns at every stage of the decision making process.

 

  1. There was no wrong doing, impropriety, or even lack of prudence in, or about, the lack of an EIA before the grant of the ODP, especially as the grant was conditional upon a number of things including the conduct of a CIA, including an EIA

 

  1. The application for judicial review was dismissed and costs were awarded against the applicants.

 

Please see a link to the referred judgement:

https://gov.tc/docs/ES_2020_CL-24_R.pdf

 

 https://gov.tc/docs/2020_CL-24_R.pdf

 

ENDS

Turks & Caicos Government

Office of the Governor

Office of the Deputy Governor

Contact

COVID-19 UPDATE